Evolution of Malignant Glioma Treatment

Price, Richard L.; Chiocca, E. Antonio

doi:10.1227/neu.0000000000000390

Cited by 19 publications

(14 citation statements)

References 98 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glioma is an invasive carcinoma of the brain with an average life expectancy of approximately 12-14 months and has poor survival rates [88]. NP systems were used to deliver drug into the brain.…”

Section: Plga-peg Co-polymeric Nps Modifications and Applicationsmentioning

confidence: 99%

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

et al. 2021

View full text Add to dashboard Cite

The blood–brain barrier (BBB) is a natural obstacle for drug delivery into the human brain, hindering treatment of central nervous system (CNS) disorders such as acute ischemic stroke, brain tumors, and human immunodeficiency virus (HIV)-1-associated neurocognitive disorders. Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible polymer that is used in Food and Drug Administration (FDA)-approved pharmaceutical products and medical devices. PLGA nanoparticles (NPs) have been reported to improve drug penetration across the BBB both in vitro and in vivo. Poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and poloxamer (Pluronic) are widely used as excipients to further improve the stability and effectiveness of PLGA formulations. Peptides and other linkers can be attached on the surface of PLGA to provide targeting delivery. With the newly published guidance from the FDA and the progress of current Good Manufacturing Practice (cGMP) technologies, manufacturing PLGA NP-based drug products can be achieved with higher efficiency, larger quantity, and better quality. The translation from bench to bed is feasible with proper research, concurrent development, quality control, and regulatory assurance.

show abstract

Section: Plga-peg Co-polymeric Nps Modifications and Applicationsmentioning

confidence: 99%

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In comparison with great improvement in the therapeutic outcomes of other types of cancer, the clinical outcomes of malignant glioma are disappointing. World Health Organization defined the anaplastic high-grade gliomas and glioblastomas as malignant gliomas [16].…”

Section: Malignant Gliomamentioning

confidence: 99%

Piperlongumine induces inhibition of the ubiquitin–proteasome system in cancer cells

Jarvius

Fryknäs

D’Arcy

et al. 2013

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

“…They are particularly aggressive and represent 80% of all malignant brain tumors (Goodenberger and Jenkins, 2012). The median survival of patients with high grade glioblastoma is only about 14 months (Price and Chiocca, 2014) with the 5-year survival almost zero (Stupp et al, 2005;Price and Chiocca, 2014). The median survival of relatively less aggressive grade III gliomas is also dismal; just two to 5 years (Wen and Kesari, 2008;Price and Chiocca, 2014).…”

Section: Introductionmentioning

confidence: 99%

Long Non-Coding RNA SNHG6 Supports Glioma Progression Through Upregulation of Notch1, Sox2, and EMT

Nie

Feng

Wang

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Gliomas, particularly the advanced grade glioblastomas, have poor 5-year survival rates and worse outcomes. lncRNAs and EMT have been extensively studied in gliomas but the disease progression remains poorly understood. SNHG6 has been shown to affect glioma cell proliferation but its effect on EMT of glioma cells along with its effect on disease progression is not known. We screened four glioma cell lines; H4, A172, U87MG, and SW088 and grouped them based on high vs. low SNHG6 expression. Transfections with SNHG6 specific siRNA resulted in induction of apoptosis of high SNHG6 expressing A172 and U87MG cells. This was accompanied by inhibition of EMT and downregulation of EMT-modulating factor Notch1, β-catenin activity and the cancer stem cell marker Sox2. The regulation was not found to be reciprocal as silencing of Notch1 and Sox2 failed to affect SNHG6 levels. The levels of SNHG6 and Notch1 were also found elevated in Grade IV glioma patients (n = 4) relative to Grade II glioma patients (n = 5). These results identify SNHG6 and Notch1 as valid targets for glioma therapy.

show abstract

Evolution of Malignant Glioma Treatment

Cited by 19 publications

References 98 publications

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP

Piperlongumine induces inhibition of the ubiquitin–proteasome system in cancer cells

Long Non-Coding RNA SNHG6 Supports Glioma Progression Through Upregulation of Notch1, Sox2, and EMT

Contact Info

Product

Resources

About